J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant

Key Takeaways JNJ secured FDA approval for subcutaneous Rybrevant Faspro across all existing NSCLC indications.The SC version cuts administration time to about five minutes versus up to an hour for IV delivery.Approval was backed by PALOMA-3 data showing Rybrevant Faspro was at least as effective as IV therapy.Johnson & Johnson (JNJ) announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab). This version, which will be marketed ...